BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target
BTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $40 price target.
Stocks · News reference
Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kazia Therapeutics Doses First Participant In Its Arm A Of PNOC035 Platform To Evaluate Paxalisib In Combination With Gemcitabine Toi Treat Atypical Teratoid/Rhabdoid Tumor
Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity
BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40